Cytochrome P450 17a1 Structures with Prostate Cancer Drugs Abiraterone and Tok-001


Cytochrome P450 17A1 (also known as CYP17A1 and cytochrome P450c17) catalyses the biosynthesis of androgens in humans. As prostate cancer cells proliferate in response to androgen steroids, CYP17A1 inhibition is a new strategy to prevent androgen synthesis and treat lethal metastatic castration-resistant prostate cancer, but drug development has been… (More)
DOI: 10.1038/nature10743


4 Figures and Tables

Slides referencing similar topics